APRAMEYA vs QMSMEDI: Stock Comparison
APRAMEYA shows a higher ROE, lower leverage and a higher ROCE, while QMSMEDI shows a lower P/E and a higher dividend yield. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
APRAMEYA leads 8; QMSMEDI leads 2 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Price
| Metric | APRAMEYA | QMSMEDI |
|---|---|---|
| Live Price | — | ₹138.13 |
| Day Change | — | 4.71% |
| Volume | — | 1.25 L |
| 52-Week High | — | ₹140 |
| 52-Week Low | — | ₹98.05 |
| Distance from 52W High | — | -1.34% |
Valuation
| Metric | APRAMEYA | QMSMEDI |
|---|---|---|
| Market Cap | ₹217 Cr | — |
| P/E Ratio | 60.82x | 12.43x |
| P/B Ratio | 0x | 1.95x |
| EPS | ₹2.68 | ₹1.38 |
| Book Value | ₹36.54 | ₹58.93 |
| Dividend Yield | 0% | 0.38% |
Growth
| Metric | APRAMEYA | QMSMEDI |
|---|---|---|
| Revenue Growth (TTM YoY) | 0% | 0% |
| EPS Growth (TTM YoY) | 0% | 0% |
| Qtr Sales Growth | 0.7% | -7.96% |
| Qtr Profit Growth | 1.73% | -32.43% |
Profitability & Leverage
| Metric | APRAMEYA | QMSMEDI |
|---|---|---|
| ROE | 7.37% | 6.42% |
| ROCE | 10.07% | 6.29% |
| Net Margin | 0% | 0% |
| Operating Margin | 19.83% | 11.39% |
| Debt to Equity | 0.1x | 0.87x |
Shareholding
As of Mar 2026 • change vs previous quarter| Metric | APRAMEYA | QMSMEDI |
|---|---|---|
| Promoter Holding | 74.05%▲ 0.52 pp | 68.11% |
| FII Holding | 0% | 0% |
| DII Holding | 0.7%▼ 0.07 pp | 1.59% |
| Public Holding | 25.24%▼ 0.46 pp | 30.3% |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: APRAMEYA and QMSMEDI.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.